Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emavusertib + Chemoimmunotherapy in Untreated Advanced Biliary Tract Cancer
NCT07107750Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emavusertib in biliary tract cancer (BTC) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Incidences and types of adverse events at 15 months and Expansion dose determination at 3 weeks. Started Mar 2026; status: recruiting.
02
Drugs
emavusertib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07107750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107750.